Literature DB >> 7997858

Effects of human calprotectin (L1) on in vitro immunoglobulin synthesis.

J G Brun1, E Ulvestad, M K Fagerhol, R Jonsson.   

Abstract

Calprotectin (L1) is a major cytoplasmic protein of neutrophilic granulocytes and monocytes/macrophages which is released from leucocytes during activation or cell death. Apart from in vitro antimicrobial and antiproliferative activity little is known about the biological function of the protein. Since previous investigations have shown that calprotectin plasma levels are elevated in various inflammatory rheumatic diseases, we wanted to investigate if calprotectin has an effect on immune cell functions. Peripheral blood mononuclear cells, either unstimulated or polyclonally stimulated with mitogen, were incubated with calprotectin and effects were assessed by enumeration of immunoglobulin secreting cells (ELISPOT). The results indicate that incubation with high concentrations of calprotectin (> 64 micrograms/ml) inhibit the production of the three classes of immunoglobulins investigated (IgG, IgM and IgA), both for mitogen stimulated and unstimulated lymphocytes. Except for the highest concentration of calprotectin (500 micrograms/ml), it seems plausible that the observed inhibitory effect of calprotectin on Ig production is not a result of a direct toxic effect of calprotection on B lymphocytes. Altogether, these effects of high calprotectin levels might be of importance in the immunoregulation of inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7997858     DOI: 10.1111/j.1365-3083.1994.tb03523.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  10 in total

1.  Loss of myeloid related protein-8/14 exacerbates cardiac allograft rejection.

Authors:  Koichi Shimizu; Peter Libby; Viviane Z Rocha; Eduardo J Folco; Rica Shubiki; Nir Grabie; Sunyoung Jang; Andrew H Lichtman; Ayako Shimizu; Nancy Hogg; Daniel I Simon; Richard N Mitchell; Kevin Croce
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

Review 2.  Non-invasive investigation of inflammatory bowel disease.

Authors:  J A Tibble; I Bjarnason
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 3.  Functional and clinical aspects of the myelomonocyte protein calprotectin.

Authors:  B Johne; M K Fagerhol; T Lyberg; H Prydz; P Brandtzaeg; C F Naess-Andresen; I Dale
Journal:  Mol Pathol       Date:  1997-06

4.  Plasma calprotectin levels in patients suffering from acute pancreatitis.

Authors:  Antonio Carroccio; Pasquale Rocco; Pier Giorgio Rabitti; Lidia Di Prima; Giovanni Battista Forte; Angelo B Cefalù; Franco Pisello; Girolamo Geraci; Generoso Uomo
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

5.  Fecal calprotectin excretion in preterm infants during the neonatal period.

Authors:  Carole Rougé; Marie-José Butel; Hugues Piloquet; Laurent Ferraris; Arnaud Legrand; Michel Vodovar; Marcel Voyer; Marie-France de la Cochetière; Dominique Darmaun; Jean-Christophe Rozé
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

6.  Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases.

Authors:  A Damms; S C Bischoff
Journal:  Int J Colorectal Dis       Date:  2008-07-16       Impact factor: 2.571

Review 7.  Functions of S100 proteins.

Authors:  R Donato; B R Cannon; G Sorci; F Riuzzi; K Hsu; D J Weber; C L Geczy
Journal:  Curr Mol Med       Date:  2013-01       Impact factor: 2.222

8.  First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.

Authors:  Peter A Anton; Terry Saunders; Julie Elliott; Elena Khanukhova; Robert Dennis; Amy Adler; Galen Cortina; Karen Tanner; John Boscardin; William G Cumberland; Ying Zhou; Ana Ventuneac; Alex Carballo-Diéguez; Lorna Rabe; Timothy McCormick; Henry Gabelnick; Christine Mauck; Ian McGowan
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

9.  Assessment of fecal calprotectin and fecal occult blood as point-of-care markers for soil-transmitted helminth attributable intestinal morbidity in a case-control substudy conducted in Côte d'Ivoire, Lao PDR and Pemba Island, Tanzania.

Authors:  Chandni Patel; Ladina Keller; Sophie Welsche; Jan Hattendorf; Somphou Sayasone; Said M Ali; Shaali M Ame; Jean Tenena Coulibaly; Eveline Hürlimann; Jennifer Keiser
Journal:  EClinicalMedicine       Date:  2021-01-30

10.  Comparison of salivary calprotectin levels in periodontitis associated with diabetes mellitus after low-level laser therapy as an adjunct to scaling and root planing: A randomized clinical trial.

Authors:  Sai Ankitha Kamatham; Vijay Kumar Chava
Journal:  J Indian Soc Periodontol       Date:  2022-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.